Annals of Hematology

, Volume 85, Issue 3, pp 185–187 | Cite as

Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease

  • Angela Casquero
  • Alicia Barroso
  • Manuel L. Fernández Guerrero
  • Miguel Górgolas
Letter to the Editor


Several approved therapies for multicentric Castleman disease (MCD) cannot be uniformly applied due to intolerable side effects. There is also a high percentage of recurrence of this disease despite treatment. Rituximab may be effective in controlling MCD in a subset of patients. This paper includes a brief case report and an extensive review of previously published cases. We observed an aggravation of concomitant cutaneous Kaposi sarcoma, and hypothesize that rituximab could have exacerbated it.


Rituximab Multicentric Castleman disease HIV Kaposi sarcoma 


  1. 1.
    Oksenhendler E, Duarte M, Soulier J et al (1996) Multicentric CD in HIV infection: a clinical and pathological study of 20 patients. AIDS 10:61PubMedCrossRefGoogle Scholar
  2. 2.
    Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard JP (2002) Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis 35:880–882PubMedCrossRefGoogle Scholar
  3. 3.
    Du MQ, Liu H, Diss TC et al (2001) Kaposi sarcoma-associated herpesvirus infects monotypic (IgMlambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 97:2130PubMedCrossRefGoogle Scholar
  4. 4.
    Marcelin AG, Aaron L, Mateus C et al (2003) Rituximab therapy for HIV-associated Castleman disease. Blood 102:2786PubMedCrossRefGoogle Scholar
  5. 5.
    Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH (2003) A case of multicentric Castleman’s disease associated with advanced systemic amyloidosis treated with chemotherapy and anti CD-20 monoclonal antibody. Ann Hematol 82:766–768PubMedCrossRefGoogle Scholar
  6. 6.
    Kofteridis DP, Tzagarakis N, Mixaki I, Maganas E, Xilouri E, Stathopoulos EN, Eliopoilos GD, Gikas A (2004) Multicentric Castleman’s disease: prolonged remission with anti CD-20 monoclonal antibody in an HIV-infected patients. AIDS 18(3):585–586PubMedCrossRefGoogle Scholar
  7. 7.
    Marrache F, Larroche C, Memain N, Bouchoud O, Robineau M, Hermone O, Lortholary O (2003) Prolonged remission of HIV-associated multicentric Castleman’s disease with anti-CD20 monoclonal antibody as primary therapy. AIDS 17:1409–1410PubMedCrossRefGoogle Scholar
  8. 8.
    Corbellino M, Bestetti G, Scalamogna C, Calattini S, Galazzi M, Meroni L, Manganaro D, Fasan M, Moroni M, Galli M, Parravicini C (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 98:3473–3475PubMedCrossRefGoogle Scholar
  9. 9.
    Newsom-Davis T, Bower M, Wildfire A, Thirlwell C, Nelson M, Gazzard B, Stebbing J (2004) Resolution of AIDS-related Castleman’s disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels. Leuk Lymphoma 45(9):1939–1941PubMedCrossRefGoogle Scholar
  10. 10.
    Ide M, Ogawa E, Kasagi K, Kawachi Y, Ogino T (2003) Successful treatment of multicentric Castleman’s disease with bilateral orbital tumour using rituximab. Br J Haematol 121:818PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Angela Casquero
    • 1
    • 3
  • Alicia Barroso
    • 2
  • Manuel L. Fernández Guerrero
    • 1
  • Miguel Górgolas
    • 1
  1. 1.Division of Infectious DiseasesFundación Jiménez Díaz-UTE, Universidad Autónoma de MadridMadridSpain
  2. 2.Pathology DepartmentFundación Jiménez Díaz-UTE, Universidad Autónoma de MadridMadridSpain
  3. 3. MadridSpain

Personalised recommendations